Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs XL 888 (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.